MRNA COVID-19 vaccination and cancer risk are examined in a case report and review that explores a reported temporal association with hematopoietic malignancy.
mRNA Vaccination and Cancer in a Reported Case
The article describes a 38-year-old woman with no significant prior medical history who developed B-lymphoblastic leukemia/lymphoma after receiving a second dose of an mRNA COVID-19 vaccine. According to the report, symptoms began the following day and included neck and jaw locking, tinnitus, nausea, diffuse pain, low grade fever, headache, and sweating. Over the following months, laboratory abnormalities progressed, with neutropenia, lymphocytosis, anemia, and a steadily rising erythrocyte sedimentation rate prompting further evaluation. PET imaging later showed intense uptake in the skeleton and spleen, and bone marrow biopsy demonstrated near-total replacement by blast-like cells consistent with precursor B-lymphoid neoplasm. The patient achieved complete remission after chemotherapy, though the paper also reports a later central nervous system relapse requiring further treatment and stem cell transplantation.
Hematopoietic Malignancies in the Literature Review
Beyond the individual case, the authors identified 30 studies, 28 of which focused on hemato-lymphoproliferative disorders following COVID-19 vaccination. These reports included B-cell, T-cell, and myeloid line malignancies, with symptom onset often described as occurring within days of inoculation. The paper notes that most published evidence consisted of case reports, and it frames these observations as signals requiring further investigation rather than definitive proof of causation. The review also highlights that specific molecular studies detailing how modified mRNA products interact with the immune system or bone marrow are still lacking.
Proposed Pathogenic Mechanisms
The review discusses several potential mechanisms that the authors believe warrant closer study. These include altered immune checkpoint signaling, reduced Type I interferon responses, increased Transforming Growth Factor Beta activity, possible effects involving p53 and BRCA pathways, IgG4 mediated immune modulation, and the broad tissue distribution of lipid nanoparticle formulations, including reported accumulation in bone marrow. The authors argue that these pathways could theoretically contribute to impaired immune surveillance or tumor promotion in susceptible individuals. At the same time, the paper acknowledges that prospective and molecular studies are still needed to test these hypotheses directly.
Clinical Interpretation and Research Need
For clinicians, the article serves primarily as a hypothesis generating report. Its central message is not that causality has been established, but that unusual temporal associations and possible biologic mechanisms should be studied more rigorously. The authors call for population based observational research, pharmacokinetic and genotoxicity assessments, and additional mechanistic work to better define whether any true carcinogenic risk exists and, if so, in which patient groups.
Reference
Gentilini P et al. Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms. Oncotarget. 2026;17:34-49.
Featured Image: Dragana Gordic on Adobe Stock.
